Vidac Pharma has not yet broken out of its sideways movement, but this is likely only a matter of time. The London-based biotech company is making good progress in cancer research and has been traded as a takeover candidate, especially since Genmab's billion-dollar acquisition of ProfoundBio. Vidac Pharma's innovative approach has the potential to revolutionize cancer treatment. The Company is researching ways to halt the proliferation of cancer cells by reversing their abnormal metabolism.
News & Events